Erudio Healtherudio.com
Drug
abiraterone acetate
3 HCP commentary reports on clinical trials studying abiraterone acetate. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| OMAHA-003 NCT06136624 · Merck Sharp & Dohme LLC | mCRPC after NHA and taxane-based chemotherapy | Phase 3 | 34 | 8 | Focused | Nov 14, 2026 | Preview |
| OMAHA-004 NCT06136650 · Merck Sharp & Dohme LLC | metastatic castration-resistant prostate cancer post one NHA | Phase 3 | 61 | 7 | Focused | Nov 14, 2026 | Preview |
| COU-AA-302 NCT00887198 · Janssen Research & Development, LLC | chemotherapy-naive metastatic castration-resistant prostate cancer | Phase 3 | 266 | 22 | Standard | Nov 14, 2026 | Preview |